Aurobindo Pharma Ltd has progressed with a major US acquisition

the FTC issued a proposed consent requiring divestiture of four generic products as a condition for approving Aurobindo’s ~USD 250m purchase of Lannett, and the company received FTC clearance to complete the deal subject to those conditions. Regulatory inspection and plant compliance developments affected sentiment: the US FDA classified Eugia Pharma Specialities (a Telangana unit) as “OAI” after inspections that found multiple observations, which led to a sharp intraday stock drop; the company has said the classification will not affect current operations.